MeSH Major Antineoplastic Agents Benzamides Gastrointestinal Neoplasms Gastrointestinal Stromal Tumors Piperazines Pyrimidines
abstract Adjuvant imatinib in patients with primary GIST who are at high risk of recurrence prolongs OS compared with that of historical controls. Optimal duration of adjuvant therapy remains undefined. (NCT00025246).
authors DeMatteo, Ronald P. Ballman, Karla V. Antonescu, Cristina R. Corless, Christopher Kolesnikova, Violetta von Mehren, Margaret McCarter, Martin D. Norton, Jeffrey Maki, Robert G. Pisters, Peter W T Demetri, George D. Brennan, Murray F. Owzar, Kouros